Although most patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) didn't respond adequately to the interleukin-17 (IL-17) inhibitor ixekizumab (Taltz), enough did that it should ...
“Most of the data on the risk of infection in patients treated with biologic/targeted synthetics disease-modifying antirheumatic drugs (b/tsDMARDs) are known from their use in other inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback